Selective Estrogen Receptor Modulators (SERMs) can be a cornerstone of pharmaceutical PCT interventions. They perform as aggressive inhibitors at estrogen receptors in the hypothalamus whilst exhibiting tissue-selective agonist or antagonist properties through the entire human body. SERMs are vital in regulating post cycle estrogen creation and mit